8-K: BiomX Announces Positive Phase 2 Results for BX211 in Diabetic Foot Osteomyelitis

BiomX reports successful Phase 2 trial results for BX211, a phage therapy targeting Diabetic Foot Osteomyelitis, showing statistically significant ulcer reduction and safety.

Summary

• BiomX Inc. announced positive topline results from its Phase 2 trial evaluating BX211 for the treatment of Diabetic Foot Osteomyelitis (DFO).
• The trial, named DANCE, was a randomized, double-blind, placebo-controlled, multi-center study.
• It investigated the safety, tolerability, and efficacy of BX211 in individuals with DFO associated with Staphylococcus aureus (S. aureus).
• The study enrolled 41 patients, with 26 receiving BX211 and 15 receiving a placebo, alongside standard of care.
• BX211 was found to be safe and well-tolerated.
• The primary efficacy endpoint, Percent Area Reduction (PAR) of the study ulcer through week 13, showed statistically significant results.
• BX211 produced statistically significant improvements in ulcer depth at week 13 in patients with ulcer depth defined as bone at baseline.
• BX211 also showed statistically significant reduction in the expansion of ulcer area compared to placebo.
• The company is planning for a Phase 2/3 trial of BX211, pending FDA feedback.
• BiomX will host a conference call and webcast to discuss the results.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results, indicating potential for a new therapy in an area with unmet needs. The sentiment is optimistic due to the statistically significant improvements and safety profile of BX211.

Positives

• BX211 was found to be safe and well-tolerated in the Phase 2 trial.
• The treatment demonstrated statistically significant reduction in ulcer size, depth, and expansion compared to placebo.
• BX211 showed efficacy against both Methicillin-susceptible and resistant strains of S. aureus.
• The results suggest a potential for BX211 to address the unmet need in DFO treatment and potentially reduce amputations.
• Favorable trends were observed in additional clinical parameters, including resolving DFO by MRI/X-ray and reduction of C-Reactive Protein.

Risks

• The Phase 2/3 trial is pending discussions and feedback from the U.S. Food and Drug Administration.
• Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of BiomX's control.
• Risks include adverse results in drug discovery, preclinical and clinical development activities, and the risk that clinical trials may not commence, continue or be completed on time, or at all.

Future Outlook

BiomX is planning for a Phase 2/3 trial of BX211, pending discussions and feedback from the U.S. Food and Drug Administration. The company expects to present additional data from the Phase 2 study at upcoming scientific conferences. Phase 2b readout for BX004 is expected in Q1 2026.

Management Comments

• Jonathan Solomon, BiomX's Chief Executive Officer, stated that the data represent one of the strongest demonstrations to date of the therapeutic potential of phage therapy.
• Dr. Robert T. Chip Schooley, M.D., noted that the promising topline data in this trial provide an important inflection point for this approach and its potential to address the most challenging infections.
• Dr. Benjamin A. Lipsky, M.D., stated that BX211 may have the potential to reduce amputations.

Industry Context

The announcement highlights the growing interest in phage therapy as an alternative to traditional antibiotics, especially in the face of rising antibiotic resistance. The positive results from BiomX's Phase 2 trial contribute to the accumulating clinical efficacy and safety data for phage therapy in the industry.

Comparison to Industry Standards

• The study mentions that no new anti-infectives have been approved in the US for DFI and DFO in the last 20 years, highlighting the unmet need in this area.
• The company references Insmed's positive results with brensocatib for treatment of NCFB, indicating the competitive landscape in the broader field of chronic inflammatory lung diseases.
• The document references tobramycin Phase 3 study as a benchmark for potential effect on PsA CFU in lungs and improved lung function (FEV1).

Stakeholder Impact

• Positive results could lead to improved treatment options for patients with DFO, potentially reducing amputations and improving quality of life.
• The company's success could benefit shareholders through increased stock value and potential revenue from BX211.
• Positive results could lead to new jobs and opportunities for employees.

Next Steps

• BiomX is planning for a Phase 2/3 trial of BX211, pending FDA feedback.
• The company expects to present additional data from the Phase 2 study at upcoming scientific conferences.
• BiomX management will host a conference call and webcast to review the topline Phase 2 trial results.
• The Company has scheduled a virtual KOL Event to discuss the topline results from the Phase 2 trial.

Key Dates

Keywords

BX211, Diabetic Foot Osteomyelitis, DFO, Phage Therapy, Clinical Trial, BiomX, Infection, S. aureus, Ulcer, Treatment